Advertisement

MMW - Fortschritte der Medizin

, Volume 161, Supplement 3, pp 69–73 | Cite as

SGLT-2-Hemmer bei Diabetes und Nephropathie

Diese Therapie wirkt auch renoprotektiv

  • Marcel RoosEmail author
FORTBILDUNG . SEMINAR
  • 41 Downloads

Für Diabetiker mit Nephropathie gibt es eine neue Therapieoption: die SGLT-2-Hemmer. Wie sie wirken und auf was Sie bei der Behandlung achten müssen, erfahren Sie im nachfolgenden Beitrag.

SGLT-2-Inhibitors and kidney function

Keywords

SGLT-2-Inhibitor kidney function glomerular filtration rate albuminuria 

Literatur

  1. 1.
  2. 2.
    KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. In: Kidney Disease: Improving Global Outcomes [KDIGO] CKD Work Group (Hrsg.): Kidney Int. Suppl. 3, Nr. 1, 2013, S. 1–150 (KDIGO CKD 2012 [PDF]).Google Scholar
  3. 3.
    Bakris et al. Treatment of diabetic kidney disease. https://www.uptodate.com/contents/treatment-of-diabetic-kidney-disease
  4. 4.
    Umanath et al. Update on Diabetic Nephropathy: CoreCurriculum 2018. Am J Kidney Dis. 71(6):884–895. Published onlineFebruary 2, 2018CrossRefGoogle Scholar
  5. 5.
    Mosenzon et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019 Aug;7(8):606–617.CrossRefGoogle Scholar
  6. 6.
    Wanner et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117–28.CrossRefGoogle Scholar
  7. 7.
    Perkovic et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295–2306.CrossRefGoogle Scholar
  8. 8.
    Thomas et al. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. 2018 Oct;61(10):2098–2107CrossRefGoogle Scholar
  9. 9.
    Zelniker TA et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;339:31–39CrossRefGoogle Scholar
  10. 10.
  11. 11.
    Peters AL. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015 Sep;38(9):1687–93.CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Diabeteszentrum BogenhausenMünchenDeutschland

Personalised recommendations